Molecular Pathogenesis of Hereditary Hemorrhagic Telangiectasia
遗传性出血性毛细血管扩张症的分子发病机制
基本信息
- 批准号:10339385
- 负责人:
- 金额:$ 47.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalACVRL1 geneActivin ReceptorAllelesAnimal ModelArteriesArteriovenous malformationBioinformaticsBloodBlood VesselsBlood capillariesBrainBrain imagingCandidate Disease GeneCephalicCharacteristicsClinicalDangerousnessDataDefectDevelopmentDiseaseDisease ProgressionDisease modelDominant Genetic ConditionsEndothelial CellsEndotheliumEtiologyEventExpression ProfilingFunctional disorderFutureGene Expression ProfileGenesGenetic DiseasesGenetic TranscriptionGenomicsGoalsHereditary hemorrhagic telangiectasiaHistopathologyHumanHypoxiaImageImmunofluorescence ImmunologicIn SituInflammationInheritedInterventionIntracranial HemorrhagesKnock-outKnowledgeLeadLesionLigandsLoxP-flanked alleleMediator of activation proteinMesenchymalModelingMolecularMusMutationNeurologicOrganPathogenesisPathologyPatientsPatternPerfusionPhysiologic arteriovenous anastomosisPre-Clinical ModelPreventive treatmentProcessProductionRNAResearchResolutionRetinaScientific Advances and AccomplishmentsShunt DeviceSignal TransductionStructureSuperoxidesTechniquesTherapeuticTimeTransforming Growth Factor betaVeinsWorkbasebioinformatics toolbone morphogenetic protein receptorsbrain dysfunctionbrain endothelial cellclinical practicedensitydrug candidategenetic associationgenome-wideinnovationmalformationmouse modelneurobehavioralnew therapeutic targetnovelnovel therapeutic interventionpostnatalpre-clinicalrational designribosome profilingsuccesstherapeutic candidatetranscriptometwo-photon
项目摘要
PROJECT SUMMARY/ABSTRACT
Arteriovenous (AV) malformations (AVMs) are vascular anomalies that shunt blood from an artery directly to a
vein, causing organ dysfunction. AVM pathogenesis is poorly understood, limiting the rational design of
molecular interventions. Our long-term goal is to develop better therapeutic treatments for AVMs, as current
treatment options are limited and risky. Our strategy is to focus on brain AVMs (BAVMs), as they are the most
dangerous AVMs, and findings in BAVM are applicable to AVMs elsewhere in the body. Most BAVMs are
sporadic, but hereditary BAVMs, such as those seen in hereditary hemorrhagic telangiectasia (HHT), offer an
excellent opportunity to study the molecular mechanism underlying disease processes. HHT is an autosomal
dominant genetic disorder characterized by multifocal AVMs throughout the body, including the brain.
Mutations in activin receptor-like kinase (ALK1) are responsible for Type 2 HHT (HHT2), which represents 25-
57% of all HHT cases. Alk1 is a type I TGFβ receptor for BMP ligands, and the mechanism through which Alk1
leads to AVMs is poorly understood. Building on our strong preliminary data, we propose to establish a novel
HHT2-BAVM mouse model, with which to identify molecular regulators crucial for AVM pathogenesis, using
both a targeted approach and unbiased genome-wide expression profiling. To this end, we propose to
establish a much-needed robust preclinical animal model that faithfully models certain aspects of disease
presentations in HHT2 patients. Existing mouse models of HHT are limited in recapitulating clinical
manifestations. Using a cutting-edge strategy, we have developed a useful mouse model of HHT2-BAVM by
deleting both Alk1 alleles specifically in brain endothelial cells, and have obtained strong preliminary data that
this deletion results in robust BAVM, intracranial hemorrhages, and neurological consequences, without
detectable defects elsewhere in the body. We will first fully characterize this model using innovative, high-
resolution two-photon imaging through a cranial window to access the vasculature in live brains, achieving a
5D perspective (3D vascular structure plus blood velocity over time). W candidate
molecular regulators that promote BAVM formation including AV programming, endothelial barrier,
inflammation, endothelial-to-mesenchymal transition, and superoxide production in mice with Alk1 deletion in
the brain endothelium. Finally, we will perform cutting-edge genomic expression profiling to elucidate Alk1
target genes, and then use bioinformatics tools to categorize identified genes based on their functional
characteristics. Our proposed Aims comprise a combination of technical and conceptual innovations that will
advance the knowledge of the molecular mechanisms underlying AVM formation and HHT pathogenesis. Our
work will establish a robust preclinical model for these diseases, uncover new molecular mechanisms
underlying the disease etiology, and impact future clinical practice for patients with HHT and BAVM.
e will also investigate
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rong Wang其他文献
Rong Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rong Wang', 18)}}的其他基金
Molecular Pathogenesis of Hereditary Hemorrhagic Telangiectasia
遗传性出血性毛细血管扩张症的分子发病机制
- 批准号:
10083767 - 财政年份:2020
- 资助金额:
$ 47.55万 - 项目类别:
Molecular Pathogenesis of Hereditary Hemorrhagic Telangiectasia
遗传性出血性毛细血管扩张症的分子发病机制
- 批准号:
9917601 - 财政年份:2020
- 资助金额:
$ 47.55万 - 项目类别:
Molecular Pathogenesis of Hereditary Hemorrhagic Telangiectasia
遗传性出血性毛细血管扩张症的分子发病机制
- 批准号:
10614453 - 财政年份:2020
- 资助金额:
$ 47.55万 - 项目类别:
Comparative Effectiveness of Treatments for Acute Myeloid Leukemia in the Elderly
老年人急性髓系白血病治疗的比较疗效
- 批准号:
8693973 - 财政年份:2013
- 资助金额:
$ 47.55万 - 项目类别:
Comparative Effectiveness of Treatments for Acute Myeloid Leukemia in the Elderly
老年人急性髓系白血病治疗的比较疗效
- 批准号:
8583443 - 财政年份:2013
- 资助金额:
$ 47.55万 - 项目类别:
Molecular pathogenesis and treatment of brain arteriovenous malformation
脑动静脉畸形的分子发病机制及治疗
- 批准号:
8117203 - 财政年份:2010
- 资助金额:
$ 47.55万 - 项目类别:
Molecular Pathogenesis of Brain Arteriovenous Malformation
脑动静脉畸形的分子发病机制
- 批准号:
9242700 - 财政年份:2010
- 资助金额:
$ 47.55万 - 项目类别:
Molecular pathogenesis and treatment of brain arteriovenous malformation
脑动静脉畸形的分子发病机制及治疗
- 批准号:
7987203 - 财政年份:2010
- 资助金额:
$ 47.55万 - 项目类别:
Molecular pathogenesis and treatment of brain arteriovenous malformation
脑动静脉畸形的分子发病机制及治疗
- 批准号:
8269939 - 财政年份:2010
- 资助金额:
$ 47.55万 - 项目类别: